Under new ownership, Pri-Med plans to expand its focus

Pri-Med is under new ownership following M|C Holding's sale of the US assets to closely held Canadian event and media producer Diversified Business Communications.  Terms of the sale were not released.

The new executive team features Pri-Med co-founder John Mooney returning as CEO, along with Lynn Long, COO and Dix Wheelock, SVP of sales. Marissa Seligman will serve as compliance officer and chief of clinical & regulatory affairs.

M|C Holding will still run  Physician's Weekly and Patient Education Center, which provides newsletters for physician offices, as well as Pri-Med's operations in Germany and the UK.

Patient- and specialist-oriented education will also be introduced on the Pri-Med platform. Targeting a collaborative audience would expand the company beyond an internist-only focus. It also reprises an idea Mooney has attempted once already.

Mooney, with Long and Wheelock, assembled a CME meeting to address specialists, primary care doctors and patients. The CollaborativeCARE Conference (C3), received considerable interest from physicians and healthcare providers but got little traction with pharmaceutical product managers and was dissolved in September.

As to why management thinks the pharmaceutical industry will support the idea this time: “We've had conversations about adding the specialty [education],” Long said, “and the response has been, ‘If you can do it at the caliber that you're doing with primary care, then we're on board.'”

After founding M|C Communications and Pri-Med in 1994, Mooney was CEO until the company's $400-million sale to Bain Capital in 2004, leaving in 2007. He started C3 in 2010.
You must be a registered member of MMM to post a comment.
close

Next Article in Features

Email Newsletters


What does going "beyond the pill" actually mean? At MM&M's recent inaugural spring conference, audience members heard from real-world companies that are managing the organizational, technological, and promotional challenges inherent in this transition, such as partnering with health neophytes, harnessing technologies that allow deeper engagement with patients, and adopting a new commercial mindset to serve, not sell. Download here.


A wave of more effective anti-cancer drugs has set the oncology world on fire with enthusiasm. While many hail this as a new era, an equally vocal faction questions the money spent for the value gained. This medical and commercial trend report for marketers of anti-cancer modalities touches on many of the latest shifts that have expedited product launches and otherwise impacted promotion and reimbursement of these drugs. Click here.